Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort

Share :
Published: 14 Nov 2019
Views: 2202
Professor Jean-Yves Blay and Professor Florence Duffaud

Bone sarcomas present a rare, heterogenous group of tumour types that include osteosarcoma. Although locoregional disease can often be treated effectively, osteosarcoma is difficult to address in the metastatic setting.

The REGOBONE trial w\s a set of phase II trials exploring the effect of the tyrosine kinase inhibitor regorafenib across different bone sarcomas. This session looks specifically at the osteosarcoma cohort, and evaluates the potential use of regorafenib in future treatment of metastatic osteosarcoma.

This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals. The educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.

To earn CME credits and discover further publication to practice sessions, please visit Oncology knowledge into practice.